Markets:

Overview

News

Currencies

International

Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

13.10 +0.08 (+0.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session

February 07, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

February 03, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

January 05, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2023

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Gold Rises Over 1%; Elys Game Technology Shares Spike Higher ↗

December 27, 2022

U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 27, 2022

Via Benzinga

Major Indexes Falter As Rocky Year Wraps Up ↗

December 27, 2022

Stocks are struggling to build on their morning gains as investors began to waver on the possibility of a

Via Talk Markets

Dow Rises 100 Points; Crude Oil Rises Over 1% ↗

December 27, 2022

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday.

Via Benzinga

Expert Ratings for KalVista Pharma ↗

October 05, 2022

KalVista Pharma (NASDAQ:KALV) has observed the following analyst ratings within the last quarter:

Via Benzinga

Where KalVista Pharma Stands With Analysts ↗

October 05, 2022

Analysts have provided the following ratings for KalVista Pharma (NASDAQ:KALV) within the last quarter:

Via Benzinga

Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session ↗

December 27, 2022

Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 27, 2022

Via Benzinga

KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering

December 27, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

December 08, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

November 14, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 07, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

October 31, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat

October 19, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman

October 17, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

October 07, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67% ↗

October 06, 2022

HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading.

Via Benzinga

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday ↗

October 05, 2022

Losers

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

October 05, 2022

Wednesday saw 127 companies set new 52-week lows.

Via Benzinga

S&P 500 Rises 100 Points; Nasdaq Up 3% ↗

October 04, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 04, 2022

Gainers

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

All News about KalVista Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today